A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial

AIM: We tested the hypothesis that dapagliflozin may regress left ventricular hypertrophy (LVH) in people with type 2 diabetes (T2D). METHODS AND RESULTS: We randomly assigned 66 people (mean age 67 ± 7 years, 38 males) with T2D, LVH, and controlled blood pressure (BP) to receive dapagliflozin 10 mg...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Eur Heart J
Hlavní autoři: Brown, Alexander J M, Gandy, Stephen, McCrimmon, Rory, Houston, John Graeme, Struthers, Allan D, Lang, Chim C
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2020
Témata:
Clinical Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8202417/
https://ncbi.nlm.nih.gov/pubmed/32578850
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/eurheartj/ehaa419
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky